A Phase III, Randomized, Open-Label, Sponsor-Blinded, Multicenter Study of Durvalumab in Combination with Tremelimumab ± Lenvatinib Given Concurrently with Transarterial Chemoembolization (TACE) Compared to TACE Alone in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-3)

drug protocol number

D910VC00001

drug sponsor

AstraZeneca

drug study

Lenvatinib (Lenvima) + Durvalumab (Imfinzi) + Tremelimumab (Imjudo)

drug trial site

King Faisal Specialist Hospital and Research Center (Riyadh) ,King Abdulaziz Medical City NG (Jeddah), King Fahad Specialist Hospital (Dammam), King Abdulaziz Medical City NG (Riyadh)

drug status

Ongoing

drug phase